ELISpot and FluoroSpot Assay Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Global ELISpot and FluoroSpot Assay Market is segmented By Product Type (Assay Kits, Analysers, Ancillary Products) By Application (Diagnostic, Research) By End User (Hospitals & Clinical Laboratories, Research Institutes, Biopharmaceutical Companies, Others) and By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Market Overview

Global ELISpot and FluoroSpot Assay Market reached US$ YY billion in 2022 and is expected to reach US$ YY million by 2031 growing at a CAGR of YY% during the forecast period 2024-2031.

ELISpot and FluoroSpot assays are the tools in immunology research and clinical diagnostics that allow the detection and quantification of cytokine-secreting cells at the single-cell level. In ELISpot assays, cytokine-secreting cells are captured by antibodies immobilized on a membrane-coated plate and the secreted cytokines are detected using enzyme-conjugated secondary antibodies and colorimetric substrates.

In FluoroSpot assays, fluorescent detection antibodies are used to visualize cytokine-secreting cells, enabling multiplex detection of multiple cytokines simultaneously. The ELISpot and FluoroSpot assays are extensively employed in evaluating immune cell function in diverse disease contexts, tracking immunological responses to infections, vaccinations, allergens, and tumor antigens, and measuring antigen-specific T cell responses.

Market Scope

For more details on this report – Request for Sample 

Market Dynamics

Increasing incidence of chronic illness

The increasing occurrence of chronic illnesses such as autoimmune disorders, HIV/AIDS, cancer, and tuberculosis drives the need for biomarkers and diagnostic instruments for disease tracking and treatment. Assays such as ELISpot and FluoroSpot provide precise and sensitive ways to measure immune responses specific to antigens and track the progression of diseases.

For instance, according to the World Health Organization (WHO) 2022 report, In 2022, an estimated 10.6 million people fell ill with tuberculosis (TB) worldwide, including 5.8 million men, 3.5 million women and 1.3 million children.

Additionally,  heart disease and cancer account for about 38% of all deaths in the United States, which makes chronic diseases one of the main causes of death. Additionally, out of every 5 Canadians aged 20 years or older, 3 have a chronic disease and 4 are at risk of developing a chronic condition. Also, according to a WHO report, 85.6 million people have been infected with HIV and about 40.4 million people have died of HIV.

Furthermore, significant growth drivers such as the rising technological advancements in vaccine development, and the rising focus on immunotherapy for the treatment of cancers, infectious diseases, and autoimmune disorders are expected to drive the market in the forecast period.

Limited assay sensitivity and specificity

The identification of low-frequency antigen-specific immune responses and separating genuine positive signals from background noise can be difficult using ELISpot and FluoroSpot assays. Also, the viability and functionality of immune cells used in ELISpot and FluoroSpot assays can impact assay sensitivity and specificity.

Segment Analysis

The global ELISpot and FluoroSpot assay market is segmented based on product type, application, end users and region.

The assay kits segment accounted for approximately 45.2% of the market share 

The assay kits segment is expected to hold the largest market share over the period forecast. ELISpot and FluoroSpot Assay kits are designed to facilitate the detection and quantification of cytokine-secreting cells at the single-cell level. These kits typically include pre-coated plates, assay buffers, detection antibodies, substrate solutions, and other necessary components for performing the assay.

Samples such as tissue digests, splenocytes, lymph node cells, and peripheral blood mononuclear cells (PBMCs) can all be used with the ELISpot and FluoroSpot diagnostic kits. Also, some ELISpot and FluoroSpot assay kits include cell stimulation reagents such as mitogens or specific antigens for stimulating cytokine production by immune cells.

For instance, in September 2022, the FDA approved Oxford Immunotec’s T-Cell Select reagent kit, which automates the workflow of the T-SPOT.TB test, a globally regulated ELISPOT IGRA that detects latent tuberculosis (TB) infection, for in-vitro diagnostic (IVD) in certified laboratories.

Geographical Analysis

North America is expected to hold a significant position in the global ELISpot and FluoroSpot assay market share

The global ELISpot and FluoroSpot assay market is segmented into North America, Europe, Asia Pacific, South America, Middle East, and Africa. 

North America has maintained a significant market proportion due to factors such as the increasing prevalence of chronic diseases, technological advancements, and increasing healthcare expenditure, this trend is anticipated to continue throughout the forecast period.

For instance, according to the National Institute of Health Report, in 2023, 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in the United States. Cancer incidence increased for prostate cancer by 3% annually.

Additionally, ImmunoSpot introduced SpotStat Software in September 2021 to facilitate statistical analysis of ELISPOT/FluoroSpot data. By providing a statistically confirmed separation between antigen-induced and negative controls, this software enhances test result accuracy.

COVID-19 Impact Analysis 

The COVID-19 pandemic has had a significant impact on the global ELISpot and FluoroSpot assay market. ELISpot and FluoroSpot assays play a crucial role in monitoring immune responses in COVID-19 patients, vaccine recipients, and individuals participating in clinical trials, leading to increased demand for these assays. However, the COVID-19 pandemic has disrupted global supply chains and manufacturing operations, leading to challenges in sourcing reagents, consumables, and assay components essential for ELISpot and FluoroSpot assays. Therefore, owing to the above factors, the ELISpot and FluoroSpot assay market was moderately affected over the forecast period.

Competitive Landscape

The major global players in the market include R&D Systems, Mabtech AB, Agilent Technologies Inc, Biocompare, Eagle Biosciences Inc., Charles River Laboratories, BIOSYS Scientific Devices GmbH, Cellular Technology Ltd, Abcam Limited, U-CyTech biosciences among others.

Why Purchase the Report?

• To visualize the global ELISpot and FluoroSpot assay market segmentation based on product type, application, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of global ELISpot and FluoroSpot assay market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global ELISpot and FluoroSpot assay market report would provide approximately 61 tables, 58 figures, and 185 Pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies